CD44 and hepatocellular carcinoma: The combination of CD24 and CD44 expression, such as CD24+/CD44+ and CD24-/CD44+, had been used to define CSCs in various other cancers, including breast, ovarian, prostate, pancreatic, colorectal, lung and renal cancer, but this had not yet been reported in HCC (131–142).